← Eichor
Study identifier: NCT03716908 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Genotype-phenotype Correlation Study of Presymptomatic and Symptomatic DFNA9 Patients

Condition: Vestibular Diseases · DFNA9  ·  Sponsor: Jessa Hospital

PhaseN/A
Planned participants70
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

DFNA9 (Deafness Autosomal Dominant 9) is an autosomal dominant hereditary hearing loss which is associated with vestibular deterioration. The most recent genotype-phenotype correlation studies have been conducted more than 15 years ago. Meanwhile, emerging and valuable vestibular tests have been added to the vestibular test battery. These tests were not available at the time of the correlation studies. The aim of this study is to carry out a prospective cross-sectional study on symptomatic and presymptomatic affected carriers of the Pro51Ser (P51S) Coagulation Factor C Homology (COCH) mutation in order to correlate vestibular data using the complete vestibular test battery with the known data on hearing and vestibular function in relation to age.

This description comes directly from the study's public registry record.

Talk to the study team

sebastien PF JanssensdeVarebeke, MD  ·  011337420  ·  sebastien.janssensdevarebeke@jessazh.be

Vincent Van Rompaey, PhD, MD  ·  038213385  ·  vincent.vanrompaey@uza.be

Always discuss trial participation with your own doctor first.

Locations (1)

University of AntwerpAntwerp, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03716908